Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC.

Arch Neurol. 2003 Jul;60(7):958-64.

PMID:
12873852
2.

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.

Arch Neurol. 2000 Jan;57(1):100-5.

PMID:
10634455
3.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
4.

Increased amyloid beta protein levels in children and adolescents with Down syndrome.

Mehta PD, Capone G, Jewell A, Freedland RL.

J Neurol Sci. 2007 Mar 15;254(1-2):22-7. Epub 2007 Feb 2.

PMID:
17275850
5.

Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J; KND-Study Group, Heuser I, Maier W, Luckhaus C, Rüther E, Hüll M, Jahn H, Gertz HJ, Frölich L, Hampel H, Pernetzki R.

J Nutr Health Aging. 2009 Mar;13(3):205-8.

PMID:
19262954
6.

Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.

Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, Hyman BT, Growdon JH, Greenberg SM, Bottiglieri T.

Neurology. 2005 Nov 8;65(9):1402-8.

PMID:
16275827
7.

Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.

De Jonghe C, Cras P, Vanderstichele H, Cruts M, Vanderhoeven I, Smouts I, Vanmechelen E, Martin JJ, Hendriks L, Van Broeckhoven C.

Neurobiol Dis. 1999 Aug;6(4):280-7.

PMID:
10448055
8.

Plasma Abeta levels do not reflect brain Abeta levels.

Freeman SH, Raju S, Hyman BT, Frosch MP, Irizarry MC.

J Neuropathol Exp Neurol. 2007 Apr;66(4):264-71.

9.

Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease.

McNamara MJ, Gomez-Isla T, Hyman BT.

Arch Neurol. 1998 Jul;55(7):1001-4.

PMID:
9678319
10.

Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.

Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M.

Brain Res. 2008 Jul 11;1219:169-79. doi: 10.1016/j.brainres.2008.02.060. Epub 2008 Mar 4.

PMID:
18534566
11.

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P.

Neurobiol Aging. 2008 Jan;29(1):1-11. Epub 2006 Oct 19.

PMID:
17055615
12.

The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.

J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.

PMID:
21440911
13.

Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.

Blasko I, Jungwirth S, Jellinger K, Kemmler G, Krampla W, Weissgram S, Wichart I, Tragl KH, Hinterhuber H, Fischer P.

J Psychiatr Res. 2008 Sep;42(11):946-55. Epub 2007 Dec 21.

PMID:
18155247
14.

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, Shi J, Stopford C, Julien C, Thompson J, Payton A, Thaker U, Hayes AJ, Iwatsubo T, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7.

15.

Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.

Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R.

Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7. doi: 10.1073/pnas.0805902105. Epub 2008 Sep 8.

16.

Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment.

Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R, Inglese ML, Volpe S, Ratto S, Dagna-Bricarelli F, Baldo C, Argusti A, Odetti P, Piccini A, Tabaton M.

Neurology. 2004 Sep 14;63(5):828-31.

PMID:
15365131
17.

Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.

Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM.

Neurology. 2006 Jan 10;66(1):23-9.

PMID:
16401840
18.

Tau load is associated with apolipoprotein E genotype and the amount of amyloid beta protein, Abeta40, in sporadic and familial Alzheimer's disease.

Thaker U, McDonagh AM, Iwatsubo T, Lendon CL, Pickering-Brown SM, Mann DM.

Neuropathol Appl Neurobiol. 2003 Feb;29(1):35-44.

PMID:
12581338
19.

Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.

Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Adamson J, Schaid DJ, Blangero J, Hutton M, Younkin SG.

Genet Epidemiol. 2001 Jul;21(1):19-30.

PMID:
11443731
20.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19.

PMID:
17374949
Items per page

Supplemental Content

Write to the Help Desk